Convalife and Jointown Partner for Global Drug Development and Commercialization
Shanghai-based Convalife Pharmaceuticals has entered into a strategic partnership with fellow Chinese firm Jointown Pharmaceutical...
Cancer
Eli Lilly’s Retevmo Wins First China Approvals for RET-Driven Cancers
Eli Lilly & Co (NYSE: LLY) has secured its first approvals in China for Retevmo...
China’s NMPA Proposes Reforms to Enhance Radiopharmaceutical Review and Approval
China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Opinions on Reforming...
Pfizer’s Talzenna Shows Positive Results in Phase III TALAPRO-2 Study for mCRPC
US-based pharmaceutical giant Pfizer (NYSE: PFE) has announced positive results from the Phase III TALAPRO-2...
Junshi Biosciences Launches PD-1 Inhibitor Tuoyi for Advanced NSCLC in China
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has held a national market...
WuXi Biologics Partners with neoX Biotech to Advance AI-Driven Drug Development
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...
Henlius Biotech Gets FDA Nod for HLX07 Clinical Study in CSCC
Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the US...
Lepu Biotechnology’s MRG003 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received Breakthrough Therapy...
Lepu Biotechnology’s PD-1 Inhibitor HX008 Gains New Indication Approval
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received another indication...
3D Medicines Partners with Denfo Medical for Cancer Therapy Development
China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group,...
Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based...
Telix Pharmaceuticals Gains IND Approval for TLX250-CDx in China
Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) has announced that it has received Investigational New Drug...
Angel Pharmaceuticals Gains CDE Approval for Mupadolimab Phase I/Ib Study
China-based Angel Pharmaceuticals Ltd has announced that it has received approval from the Center for...
Shuangcheng Pharma Licenses US Rights for Paclitaxel Injection to Meitheal
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) has announced a licensing and supply agreement...
Nerviano Medical Sciences Collaborates with Merck on PARP1 Inhibitor NMS-293
Italy-based Nerviano Medical Sciences S.r.l. (NMS), which is 90% owned by Chinese investment fund SARI...
AstraZeneca and Merck’s Lynparza Receives New Approval in China
UK-based AstraZeneca (NASDAQ: AZN) and US-based Merck, Sharp & Dohme (MSD, NYSE: MRK) have announced...
Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA
China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...
CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit
China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...
BeiGene’s Brukinsa Receives New EU and UK Indications for BTK Inhibitor
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has received two new indication...
Alphamab Oncology Doses First Patient in Phase I Study for JSKN003 in Australia
Alphamab Oncology (HKG: 9966) has announced that the first patient has been dosed in a...